Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool November 11, 2004 Brian Gorman	Hospira's Possibilities The medical products and services outfit is not flashy, but it may benefit from long-term trends. Their stock may be worth monitoring.
BusinessWeek September 22, 2003	This Baby May Outdo Its Parent Some orphans are better off without their parents -- corporately speaking, that is. My hunch is this may apply to shares due to spring forth next year from health-care giant Abbott Laboratories.
The Motley Fool August 10, 2006 Stephen D. Simpson	Volatility, Thy Name Is Hospira Margins continue to stand in the way of consistent performance at the health-care company. Investors, take note.
The Motley Fool June 2, 2005 Brian Gorman	Hospira's Little Purchase There may be more to Hospira's recent acquisition than meets the eye.
The Motley Fool May 9, 2006 Stephen D. Simpson	Riding the Hospira Yo-Yo There's a solid foundation on this roller coaster pharmaceutical and drug delivery company. Maybe Hospira's current valuation doesn't make it a "gem," but that's not really within its control.
The Motley Fool November 10, 2005 Stephen D. Simpson	Hospitable Treatment for Hospira Solid margins fuel strong earnings at the hybrid generics - medical distributor. Buying this stock wisely may be the key to good long-term returns.
The Motley Fool November 9, 2006 Brian Lawler	Hospira's Flatlining Sales There's no good news to be found in this medical products supplier's medicine chest. The upcoming fourth quarter isn't going to be any better, either. Investors, take note.
The Motley Fool May 13, 2005 Brian Gorman	Hospira's Hopeful Signs The medical products company's strong quarter belies a less exciting future. Investors should probably take a wait-and-see attitude.
The Motley Fool March 1, 2006 Brian Gorman	Hospira's Stumble In spite of an unsightly quarter, good things still are happening at this medical products and services outfit. Investors, take note.
The Motley Fool January 20, 2011 Jeremy Phillips	Time to Sell Hospira? Hospira has failed two of the quick tests that would make it a sell. This is great, but does it mean you should hold your Hospira shares?
The Motley Fool September 22, 2006 Brian Lawler	Hospira's New Mate Down Under The specialty injectable pharmaceutical announces an acquisition, but the move means adding on a lot more debt. Investors, take note.
The Motley Fool August 8, 2007 Ryan Fuhrmann	Hospira Looks to Deliver Will a recent acquisition boost drug delivery firm Hospira's growth prospects? The new Mayne Pharma Limited division played a primary role in delivering an impressive 30% reported sales growth.
The Motley Fool October 20, 2005 Stephen D. Simpson	Baxter Needs Growth Infusion This is a fine health-care company, but a sluggish top line suggests there are limits to how far it can go. Trading at nearly 20 times forward earnings, it seems like expectations of a growth revival are already in the stock.
The Motley Fool February 23, 2004 Brian Gorman	Abbott Cleans Up Its Act Abbott closes the books on its problems with the FDA and clears the way to a spinoff. Abbott finally passed FDA muster with its Illinois diagnostics plant. Its multi-year problem highlights the importance of investors monitoring manufacturing while watching a pharmaceutical company's pipeline. And with its FDA compliance issues behind it, Abbott can look forward to spinning off its Hospital Products Division.
IndustryWeek September 1, 2006 David Blanchard	Hospira CEO Chris Begley -- Diagnosis: Green and Lean Chris Begely says manufacturers should become more environmentally responsible. What's more, he's doing something about it.
The Motley Fool April 12, 2004 Brian Gorman	Abbott Not Rewarded Abbott Laboratories first-quarter earnings news was positive, but investors didn't react enthusiastically.
The Motley Fool July 9, 2004 Phil Wohl	Abbott Labs Concocts Strong Q2 The drug maker reports earnings as expected and refines its third-quarter guidance.
The Motley Fool January 5, 2010 Brian Orelli	A Deal Manufactured by Necessity Genzyme gets some help from a new friend.
The Motley Fool July 13, 2005 Stephen D. Simpson	Is Abbott's Ailment Serious? There's room for improvement at Abbott Labs, but this is one solid and broadly diversified company. Shares aren't a screaming bargain, but the current price-to-earnings ratio really isn't out of line with history.
The Motley Fool March 20, 2007 Brian Lawler	Smart Move by Abbott? Abbott takes a drastic measure to make a point about its patents. Thailand's actions offer a good warning of what can happen when governments try to intervene too much in existing markets.
The Motley Fool December 9, 2009 Brian Orelli	Welcome to Club Biogeneric, Pfizer! The megadrugmaker jumps on the biogeneric bandwagon.
The Motley Fool January 31, 2006 Stephen D. Simpson	Guidance Puts ICU Medical in the Trauma Ward This oft-volatile stock had a strong fourth quarter, but weak guidance. Even with today's steep drop in price, the shares aren't cheap enough to be interesting.
Chemistry World February 12, 2015 Rebecca Trager	Hospira buyout is a shot in the arm for Pfizer's biosimilars Pfizer said in a statement that its acquisition of Hospira will create 'a leading global sterile injectables business.
The Motley Fool March 1, 2007 Brian Lawler	Hospira's Boring Growth The medical products provider announces its fourth quarter financial results and gives guidance for 2007. Investors, take note.
Chemistry World May 21, 2014 Phillip Broadwith	Abbott to buy Chile's CFR for $3bn The move will bolster Abbott's position in the rapidly growing markets of Latin America.
The Motley Fool October 18, 2006 Brian Lawler	Is a Buyback the Best Abbott Can Do? Abbott Labs may be out of ideas for its cash. Investors, take note.
The Motley Fool September 24, 2008 Brian Orelli	Hey, You! Stop! The FDA has ordered Baxter and Hospira to stop making their ophthalmic balanced salt solutions within 60 days.
The Motley Fool November 20, 2006 Brian Gorman	Hospira's Bold Move The drug delivery outfit's stab at biosimilars is worth some attention, but investors shouldn't assume a major payoff.
The Motley Fool June 29, 2010 Brian Orelli	Redeploying Capital? Investors Hope So. Selling a business unit won't help Abbott Labs diversify.
The Motley Fool October 20, 2011 Brian Orelli	Mini J&J? I Guess Not Abbott says it plans to split in two: drugs in one company, everything else in the other.
BusinessWeek January 29, 2007 Michael Arndt	Abbot Labs: Diagnosis: Shrewd Moves Abbott Laboratories has announced that it is selling about two-thirds of its $4 billion diagnostics business to buy more medical products outfits to help boost overall sales and profits by at least 10% a year into the next decade.
The Motley Fool October 19, 2005 Stephen D. Simpson	ICU, You Look Healthier An incredible third quarter shows what operating leverage can do for this little medical technology company. Investors, take note.
The Motley Fool September 10, 2010 Anand Chokkavelu	How Expensive Is Abbott Laboratories Stock Right Now? Abbott Laboratories has a mixed performance in hitting the ideal targets, but let's see how it compares against some competitors and industry mates.
The Motley Fool May 11, 2010 Brian Orelli	Abbott Makes a Push Into Selling Leftovers Abbott Labs has jumped on the established-product-division bandwagon. The company has licensed 24 products from Zydus Cadila of India and has the option to market another 40.
The Motley Fool July 29, 2010 Brian Orelli	Is Abbott a Buy? Whether or not Abbott is a buy depends on management's ability to transition the company.
The Motley Fool November 8, 2011 Brian Wilson	2 Health-Care Stocks for Times of Uncertainty Just because Abbott and Johnson & Johnson don't undertake as much risk as other health-care giants doesn't mean that shareholders won't see impressive growth in revenues.
The Motley Fool April 20, 2006 Stephen D. Simpson	More Predictable Unpredictability at ICU Hidden beneath all of the volatility is a pretty decent med-tech business. Recent volatility was the kind that investors like. The stock spiked up as earnings exceeded analyst estimates and the business did a fair bit better than management had projected at the end of last quarter.
The Motley Fool July 8, 2008 Brian Orelli	Now That's the Way to Spin Off a Company The two spin-off companies formed from Abraxis Pharmaceutical, APP Pharmaceuticals and Abraxis BioScience, are worth almost double the value their parent had before the sale.
The Motley Fool September 12, 2007 Brian Orelli	Fitting Fission at Abraxis BioScience Abraxis BioScience will split itself into a biotech firm and a generic drug business. Both new companies stand to benefit, but will investors?
The Motley Fool July 19, 2005 Stephen D. Simpson	Peek-a-Boo ICU ICU Medical has taken on quite a bit of risk in the process of remaking the company. It's best to wait for a reasonable valuation before buying shares.
The Motley Fool July 8, 2010 Selena Maranjian	Get 2-for-1 Stock-Price Growth This one-two punch can lead to serious gains. Stocks that offer both earnings growth and P/E growth can help you rack up knockout returns over the long haul.
The Motley Fool February 20, 2008 Brian Orelli	Abbott's Copycat Combinations Abbott's latest FDA approval is for Simcor, a combination of Niaspan -- Abbott's slow-release niacin -- and the active component of Merck's Zocor, which isn't patent-protected anymore. Investors take note.
The Motley Fool September 30, 2008 Brian Orelli	Cardinal Health Clips Its Wings Does it make sense for the drug wholesaler to spin off its medical equipment business?
The Motley Fool October 19, 2005 Stephen D. Simpson	Abbott Still a Little Pale Perhaps drug and device pipelines, plus margin improvements, can put some color back into the diversified health-care company's stock.
IndustryWeek June 1, 2007 Traci Purdum	500 Largest U.S. Manufacturers: Manufacturing Giants This group of manufacturing leaders is demonstrating how to stay competitive in a global economy.
The Motley Fool December 1, 2009 Brian Orelli	Abbott Makes All the Right Moves Hot off its cholesterol win over Merck, Abbott Labs is playing it safe with another cholesterol drug, TriCor.
The Motley Fool January 23, 2007 Ralph Casale	Win-Win for Abbott and GE? Abbott trades its medical diagnostics segment for cold hard cash. Will shareholders see this deal as a win-win scenario? Investors, take note.
The Motley Fool January 22, 2009 Brian Orelli	Abbott Labs Thumbs Nose at Recession On a GAAP basis, Abbott Labs fourth-quarter earnings per share were up a whopping 27%, and even better, the double-digit increases don't look like they're going to stop anytime soon.
The Motley Fool November 15, 2011 Dan Caplinger	Has Abbott Labs Become the Perfect Stock? For long-term investors, Abbott's continuing devotion to up its dividend -- its streak now stands at 39 years -- makes a compelling reason to hold onto your shares.
The Motley Fool October 14, 2009 Brian Orelli	Consistency Makes This Stock a Winner Abbott turns in a solid quarter, but it needs to keep branching out.